|Bid||40.72 x 1400|
|Ask||43.09 x 1000|
|Day's Range||42.07 - 42.57|
|52 Week Range||37.43 - 45.62|
|Beta (3Y Monthly)||0.42|
|PE Ratio (TTM)||21.93|
|Forward Dividend & Yield||1.86 (4.48%)|
|1y Target Est||49.75|
Ascendis Pharma (ASND) submits regulatory application to initiate a phase II study in the United States on its hypoparathyroidism therapy candidate, TransCon PTH.
Sanofi (SNY) and Regeneron (REGN) announce a 60% cut in the U.S. list price of their cholesterol lowering drug, Praluent to improve access and affordability of the product.
February 12, 2019 - Sanofi has appointed Ameet Nathwani, M.D. as Chief Digital Officer in addition to his current role of Executive Vice President, Chief Medical Officer. As Chief Digital Officer, Dr. Nathwani will be responsible for enhancing Sanofi`s strategy to integrate digital technologies and medical science to ultimately improve patient outcomes.
A growing effort to push back on price increases is affecting pharmaceutical companies. Regeneron and Sanofi are the latest to announce a cut, for the cholesterol drug Praluent.
Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug. The new list price for Praluent will be $5,850 (£4,533) a year, matching the price Amgen set when it lowered the list of its competing drug, Repatha, in October.
BRIDGEWATER, N.J. and TARRYTOWN, N.Y., Feb. 11, 2019 /PRNewswire/ -- Praluent® (alirocumab) will be made available at a new reduced U.S. list price of $5,850 annually, a 60% reduction from the original price, for both the 75 mg and 150 mg doses, beginning in early March. The new lower-priced Praluent is expected to result in lower patient out-of-pocket costs and represents another step in the companies' efforts to help improve patient affordability and access. This follows an earlier announcement in March 2018, when Sanofi and Regeneron committed to lower the U.S. net price for payers in return for helping to reduce burdensome access barriers for appropriate patients.
Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug. The new list price for Praluent will be $5,850 a year, matching the price Amgen set when it lowered the list of its competing drug, Repatha, in October.
are slashing the list price of anti-cholesterol drug Praluent by 60 per cent, as the drugmakers respond to pressure from US health insurers and pharmacy benefit managers reluctant to adopt the costly medicine. Praluent will have a list price of $5,850 a year from early March, down from about $14,000 previously. The price cut is designed to make the drug more affordable for older patients using Medicare, cutting out-of-pocket costs to between $25 and $150 a month, depending on the plan.
Sanofi SA (SNY) reported fourth-quarter and full-year 2018 earnings before the opening bell on Thursday. The French health care major posted business earnings of 1.10 euros ($1.25) per share for the last quarter of 2018, reflecting 4.7% year-over-year growth at constant exchange rates. Driven by strong performance in the rare disease unit Genzyme, revenue came in at 8.997 billion euros, growing 3.9% year over year at constant exchange rates .
Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 6) Array Biopharma Inc (NASDAQ: ARRY ) Millendo Therapeutics ...
PARIS , Feb. 7, 2019 /PRNewswire/ -- Sanofi (NASDAQ: SNY; EURONEXT: SAN) Q4 2018 Change Change at CER 2018 Change Change at CER IFRS net sales reported €8,997m +3.5% +3.9% €34,463m -1.7% +2.5% IFRS net ...
Olivier Brandicourt, the chief executive of Sanofi, said on Thursday that its recent restructuring was starting to bear fruit as the French pharmaceutical group vowed to increase profit this year with new launches. “Our strategic transformation has brought fruit this year,” Mr Brandicourt told journalists, as Sanofi outlined its full-year results for 2018. At constant exchange rates, its earnings per share increased 5.1 per cent, which is at the upper end of the company’s target.
The Paris-based company said it had profit of 11 cents per share. Earnings, adjusted for non-recurring costs, were 63 cents per share. The results surpassed Wall Street expectations. The average estimate ...
SA (SAN.FR) said Thursday that its fourth-quarter sales and business net income grew. Business net income, an important adjusted metric for the company, grew 4.3% to 1.4 billion euros ($1.6 billion) in the fourth quarter, the company said. Excluding Animal Health gains on disposal, full-year IFRS net income was up 14.5% and full-year IFRS EPS was up 15.3%, the company said.
French drugmaker Sanofi on Thursday pledged further increases in full-year profit helped by new drug launches and its reorganisation efforts. It forecast an increase of 3-5 percent in 2019 earnings per share as it posted slightly higher-than-expected quarterly earnings, powered once again by its rare diseases Genzyme unit. Sanofi, whose struggle to find new products has weighed on previous earnings as diabetes patents expired, is placing its hopes on the success of its new rare blood disorder franchise and a continued upswing for its eczema treatment Dupixent.
Sanofi on Thursday pledged further increases in full-year profits, helped by new drug launches and reorganisation efforts. The French drugmaker said it expected net income to increase by 3-5 percent in 2019 as it posted slightly higher-than-expected quarterly earnings powered once again by its rare diseases Genzyme unit. Sanofi, whose struggle to find new products has weighed on previous earnings as diabetes patents expired, is placing hopes on the success of its new rare blood disorder franchise and a continued upswing for its eczema treatment Dupixent.
Drugmakers Pfizer Inc, Bristol-Myers Squibb Co and Sanofi SA said on Wednesday that their chief executives plan to testify at a Senate hearing on rising prescription drug prices later this month. Johnson & Johnson said on Wednesday that Jennifer Taubert, its head of global pharmaceuticals, would represent the healthcare conglomerate at the hearing.
February 6, 2019 - At its meeting held on February 6, 2019, the Board of Directors duly noted the resignation of Mr. Mulliez and decided, after consultation of the Appointments and Governance Committee, to co-opt Christophe Babule as Director for the remainder of Christian Mulliez`s term of office (expiring at the end of the Annual Shareholders` Meeting held in 2022 to approve the financial statements for the fiscal year ending December 31, 2021). The co-optation of Christophe Babule will be subject to ratification by the next Shareholders` Meeting of Sanofi, on April 30, 2019. On November 19, 2018 Christophe Babule has been appointed Executive Vice-President, Chief Financial Officer and member of L`Oréal`s Executive Committee as of mid-February 2019.